Sign In
Buy CRMD
$8.23
+0.0600 (+0.734%)
At Close: Jun 03, 2026
CorMedix (CRMD) Moves to Buy: Rationale Behind the Upgrade
04:00pm, Thursday, 21'st May 2020
CorMedix (CRMD) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Analyst Forecasts Just Got A Whole Lot More Bearish On CorMedix Inc. (NYSEMKT:CRMD)
12:48pm, Sunday, 17'th May 2020
Today is shaping up negative for CorMedix Inc. (NYSEMKT:CRMD) shareholders, with the analysts delivering a substantial...
B. Riley FBR Maintains Buy on Cormedix, Raises Price Target to $12
11:45am, Tuesday, 12'th May 2020CorMedix, Inc. (CRMD) CEO Khoso Baluch on Q1 2020 Results - Earnings Call Transcript
01:16am, Tuesday, 12'th May 2020
CorMedix, Inc. (NYSEMKT:CRMD) Q1 2020 Earnings Conference Call May 11, 2020, 16:30 ET Company Participants Daniel Ferry - LifeSci Advisors Khoso Baluch - CEO &a
CorMedix (CRMD) Reports Q1 Loss, Misses Revenue Estimates
11:35pm, Monday, 11'th May 2020
CorMedix (CRMD) delivered earnings and revenue surprises of 8.70% and -48.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Cormedix Q1 EPS $(0.210) Beats $(0.230) Estimate, Sales $75.054K Miss $170.000K Estimate
08:15pm, Monday, 11'th May 2020CorMedix Inc. Reports First Quarter 2020 Financial Results and Provides Business Update
08:10pm, Monday, 11'th May 2020
BERKELEY HEIGHTS, N.J., May 11, 2020 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the.
BRIEF-Cormedix Inc. Announces Appointment Of Chief Financial Officer
12:47pm, Monday, 11'th May 2020
* SAYS MATT DAVID APPOINTED CFO Source text for Eikon: Further company coverage:
CorMedix Inc. Announces Appointment of Chief Financial Officer
12:30pm, Monday, 11'th May 2020
CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseas
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
12:00am, Sunday, 10'th May 2020
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
CorMedix Hosting KOL Call on Antimicrobial Resistance, Catheter-Related Bloodstream Infections (CRBSIs), and the Potential for Neutrolin®
12:30pm, Wednesday, 06'th May 2020
CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,
CorMedix Inc. to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 11
01:00pm, Monday, 04'th May 2020
CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,
CorMedix Inc. Announces Contract Extension of Jack Armstrong as Executive Vice President and Head of Technical Operations
12:15pm, Thursday, 23'rd Apr 2020
CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,
Top Ranked Momentum Stocks to Buy for April 22nd
03:50pm, Wednesday, 22'nd Apr 2020
Top Ranked Momentum Stocks to Buy for April 22nd
